An experimental gene-editing therapy developed by CRISPR Therapeutics has demonstrated potential in addressing heart disease by significantly reducing high cholesterol levels. The treatment, which targets a gene in the liver called ANGPTL3, successfully lowered ‘bad’ LDL cholesterol and triglycerides by an average of 50 percent in a trial involving 15 participants. This finding, presented at the American Heart Association’s annual meeting and published in The New England Journal of Medicine, highlights the potential of CRISPR technology beyond rare diseases.
CRISPR Therapeutics, known for its Casgevy treatment for sickle cell disease and beta thalassemia, sees this development as a significant milestone in medical applications of gene editing. With approximately a quarter of US adults having elevated LDL levels and a similar number facing high triglycerides, this innovation could offer a new approach to combating heart-related risks associated with these conditions.
The Phase I trial, conducted in multiple countries, showcased the sustained impact of the gene-editing therapy on cholesterol levels, providing hope for a broader application of CRISPR technology in treating common health issues.
Source: WIRED